Insider Cluster (3 insiders) ·Filed May 26, 2026

BCAX

Bicara Therapeutics Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago
Insider cluster: 3 insiders, $0.6M total
Actionable Insight • Neutral

This cluster is routine and non-informational. The CFO's sale is a textbook cashless exercise pattern, and the CEO/COO sales are small relative to market cap. No bearish read-through. Monitor the next 10-Q for pipeline updates on BCAX's lead candidate; insider activity here provides no edge.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
BCAX ▲ +13.02% at T+60d
NEUTRAL call ✓ call won +13.02% · α vs SPY +11.14% · entry $21.58 → $24.39
Entry anchored
May 26, 2026
via day open
T+1d
+0.79%
call +0.79% · α +0.24%
$21.75
settled 4mo ago
T+5d
-7.32%
call -7.32% · α -7.79%
$20.00
settled 4mo ago
T+20d
+22.06%
call +22.06% · α +23.96%
$26.34
settled 3mo ago
T+60d
+13.02%
call +13.02% · α +11.14%
$24.39
settled 6w ago

Price Chart

Loading chart...

Executive Summary

Three top BCAX insiders (CEO, CFO, COO) sold a combined $590K in open-market shares over a 7-day window. The CFO's sale was a same-day cash-out of exercised options, while the CEO and COO sold directly. At $1.4B market cap, the total represents ~0.04% — well below the 0.1% materiality threshold — making this a routine, non-informational cluster. The CFO's option exercise and immediate sale is a classic tax/vesting pattern, not a bearish signal.

Key Financial Metrics

Direction
selling
Total Value
$590.0K
Insiders
3

Key Facts

  • Three C-suite insiders (CEO, CFO, COO) sold shares totaling $590K in open-market transactions between May 15-21, 2026.
  • CFO Hyep Ivan exercised 9,200 options at $0 and $3.79, then immediately sold the same shares at $20.42 — a standard cashless exercise pattern.
  • Total cluster value of $590K represents ~0.04% of BCAX's $1.4B market cap, well below the 0.1% materiality threshold.
  • No insider purchases were reported in the cluster; all three transactions were sales.

Financial Impact

Total insider sales of $590K, or ~0.04% of market cap — immaterial.

insider holdings

Risk Factors

  • Insider sales could accelerate if upcoming clinical data disappoints, but this cluster shows no unusual pattern.
  • No insider buying to signal confidence in upcoming catalysts.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
80% bullish (20 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-BCAX-1779832121031
20 reports for BCAX
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for BCAX — sortable, filterable
TypeNow
Aug 25, 2026
5w ago
8-K
NEUTRAL ★ 2/10
$24.73 $19.78▼ −20.02%▼ −20.24%$18.25 (−26.18%)
Aug 14, 2026
7w ago
Press Release
NEUTRAL ★ 2/10
$24.28 $23.20▼ −4.45%▼ −2.46%$18.25 (−24.81%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 5/10
$23.63 $22.81▼ −3.47%▼ −1.72%$18.25 (−22.75%)
Aug 12, 2026
7w ago
Insider Cluster
NEUTRAL ★ 4/10
$23.63 $22.81▼ −3.47%▼ −1.72%$18.25 (−22.75%)
Aug 11, 2026
7w ago
8-K
MIXED ★ 6/10
$23.76 $23.64▼ −0.51%▲ +0.55%$18.25 (−23.17%)
Aug 11, 2026
7w ago
Press Release
MIXED ★ 6/10
$23.76 $23.64▼ −0.51%▲ +0.55%$18.25 (−23.17%)
Jul 14, 2026
11w ago
Insider Cluster
NEUTRAL ★ 2/10
$28.10 $23.76▼ −15.44%▼ −17.94%$18.25 (−35.04%)
Jun 11, 2026
16w ago
Institutional Cluster
BEARISH ★ 5/10
$21.28 $29.68▼ −39.47%▼ −37.58%$18.25 (+14.22%)
May 26, 2026
18w ago
Insider Cluster
NEUTRAL ★ 2/10
$21.58 $26.34▲ +22.06%▲ +23.96%$18.25 (−15.41%)
May 11, 2026
20w ago
8-K
NEUTRAL ★ 4/10
$22.92 $20.56▼ −10.30%▼ −9.99%$18.25 (−20.35%)
Showing 10 of 20

US Market Status

Market Open — Closes in 3h 55m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access
Report published May 26, 2026